Skip to main content

The Globe and Mail

Valeant to sell its Obagi skin-care business for $190-million

The stock price of Valeant Pharmaceuticals International, Inc. is shown on a screen above the floor of the New York Stock Exchange.


Valeant Pharmaceuticals International Inc, said on Monday it would sell its Obagi Medical Products business for $190-million in cash, as part of the Canadian drugmaker's efforts to cut down its debt.

Valeant, which bought the Irvine, California-based Obagi for about $344-million in 2013, will sell the business to Haitong International Zhonghua Finance Acquisition Fund I LP.

The Obagi Medical Products unit includes skin-care products designed to help minimize the appearance of premature skin aging, skin damage and hyperpigmentation, the company said.

Story continues below advertisement

Proceeds from the deal, which is expected to close in the second half, will be used to further repay term loan debt, Valeant said.

U.S.-listed shares of the company reversed course and were up 1.2 per cent at $17.45 in premarket trading. They had gained about 37 per cent since June 1.

The drugmaker has been looking to reduce its debt pile of about $29-billion as of March 31, following a furious spate of deal-making under former CEO Mike Pearson.

Valeant said last week it paid down $811-million of debt with proceeds from the sale of its cancer treatment unit Dendreon Pharmaceuticals.

Limited partners of the Haitong fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Ltd.

Morgan Stanley is Valeant's financial adviser, while Norton Rose Fulbright the legal adviser.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
We have temporarily removed commenting from our articles. We expect to have our new commenting system, powered by Talk from the Coral Project, running on our site by the end of April, 2018. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to